LATEST ARTICLES
- Lilly claims promising finding in failed study of COVID-19 drug
- With new data, Merck could be first to bring immunotherapy to early kidney cancer
- Biogen adds a late-stage prospect to its growing biosimilar business
- Gilead wins full approval for drug acquired in Immunomedics deal
- AstraZeneca’s coronavirus vaccine possibly linked to rare blood clots, EMA says
- FibroGen admits misleading safety data for anemia drug, dimming prospects
- NLSDays goes digital for 2021 and is set to welcome key players in the life science industry from across the globe
- Metrion Biosciences closes £2.7m new equity financing
- UniQure says hemophilia gene therapy likely not cause of study volunteer’s cancer
- Amgen acquires a small biotech and its inflammatory disease research
